Terremoto Biosciences Inc.
Clinical trials sponsored by Terremoto Biosciences Inc., explained in plain language.
-
New drug aims to stop debilitating nosebleeds in rare disease
Disease control Recruiting nowThis is the first human trial for a new drug called TER-1754, designed for people with hereditary hemorrhagic telangiectasia (HHT), a disorder that causes frequent, severe nosebleeds and other bleeding problems. The main goal is to find a safe dose and see if the drug can reduce …
Phase: PHASE1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New cancer drug targets common genetic pathway in multiple tumors
Disease control Recruiting nowThis study is testing a new drug called TER-2013 in people with advanced solid tumors that have specific genetic changes. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for patients who have run out of standard treatment options.
Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC